-2.81%
Today
Loading 1D prices…
Company profile
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Sector
Health Care
Industry
Services-Medical Laboratories
Exchange
Nasdaq
Display currency
USD
Location
South San Francisco, CA, United States
Employees
755
Fiscal year end
1231
CIK
1384101
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| GRALGRAIL Inc. Common Stock | $3.4B | $147.2M | -277.47% | -$11.11 | -1.83% | Hold |
| CELCCelcuity Inc. Common Stock | $4.1B | $0.00 | — | -$3.79 | -2.39% | Buy |
| CDNACareDx Inc. Common Stock | $2.6B | $379.8M | -5.62% | -$0.40 | +0.48% | Buy |
| BLLNBillionToOne Inc. Class A Common Stock | $4.7B | $305.1M | +2.44% | $0.14 | +0.26% | Buy |
| RDNTRadNet Inc. Common Stock | $5.9B | $2B | -0.91% | -$0.25 | +1.60% | Buy |